At a $1,454M market cap with negative EPS of -26.6 and no calculable P/E or Forward P/E, the market is not valuing this as a growth compounder but as a distressed asset. The Altman Z-Score of 0.9 is deep in distress territory, and with operating margins at -18.30% and ROIC at -10.30%, capital is being destroyed rather than compounded. Price/Book at 0.9 suggests the equity trades slightly below accounting value, but that discount is justified given persistent losses and negative forward earnings of -$9.97. This is not a mispriced growth story; it is a balance-sheet-dependent restructuring situation where survival, not expansion, is the core question.
⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.